Biohaven Ltd (BHVN)

$9.20 +0.12 (1.32%)
Market Cap 1.37B
Revenue (ttm) 0.00
Net Income (ttm) -738.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.87
Volume 1,818,500
Avg Vol 2,194,708
Day's Range N/A - N/A
Shares Out 150.56M
Stochastic %K 18%
Beta 1.32
Analysts Strong Sell
Price Target $22.35

Company Profile

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinica...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 404 0410
Address:
215 Church Street, New Haven, United States
Ilygod
Ilygod May. 13 at 12:30 PM
$BHVN Institutions have been accumulating. You have to wonder if large Pharma is waiting for a change in FDA stance on SCA drug. If so, I bet it gets bought out for $25.
0 · Reply
Timefortendies77
Timefortendies77 May. 12 at 11:14 PM
$BHVN I didn't catch this before but after March 16 meeting with BHVN CEO and FDA CC, this meeting happened---Meeting Details from the FDA CalendarDate: April 30, 2026.Participants: Vlad Coric (CEO of Biohaven) and Several FDA staff members. Subject: Listed as "Issues of Mutual Interest"
0 · Reply
Timefortendies77
Timefortendies77 May. 12 at 11:08 PM
$BHVN Kyle D has the potential to be a "breath of fresh air" for industry relations compared to Marty, but whether he is "better" depends on your definition of success. M's tenure was defined by constant friction with pharmaceutical CEOs, mass staff departures, and erratic policy fights. [1, 2] Early market reactions to D’s appointment on May 12, 2026, suggest a cautiously optimistic view from the business community: [1] • Pragmatism Over Polemics: Unlike M, who frequently engaged in public spats, industry officials describe D as pragmatic, knowledgeable, and easier to work with. • A "Broad Positive" for Biopharma: Analysts from BioSpace noted that moving on from M could restore a level of predictability and trustworthiness to the regulator that was lost during the recent leadership churn.
0 · Reply
Timefortendies77
Timefortendies77 May. 12 at 10:55 PM
$RGNX Hi RGNX ---it's your pals over at $BHVN. What's the word on getting your drug reassessed given the change in FDA leadership?
2 · Reply
Timefortendies77
Timefortendies77 May. 12 at 10:53 PM
$BHVN Remember this tweet? @US_FDA exploring path forward for therapies that received CRLs $BHVN , $RGNX , Sydnexis held meetings w FDA’s chief counsel, Sean Keveney, following high-profile regulatory setbacks. Such meetings are highly unusual, writes BioCentury Washington Editor https://x.com/jeff_cranmer/status/2039127714599440671
0 · Reply
Timefortendies77
Timefortendies77 May. 12 at 10:51 PM
$BHVN BYE BYE MARTY! Time for our CRLed drug to get reassessed.
0 · Reply
jfoyle
jfoyle May. 12 at 5:26 PM
$BHVN He is officially gone! Huge re-rating coming for BHVN! https://www.nbcnews.com/health/health-news/dr-marty-makary-fda-commissioner-rcna344765
0 · Reply
Timefortendies77
Timefortendies77 May. 12 at 5:10 PM
$BHVN 8.85-9 is a gift with a significant update coming.
0 · Reply
jfoyle
jfoyle May. 12 at 3:11 PM
$BHVN Anything below $9 is a gift! May 27th on R&D day we will see a significant re-rating. Mark this post
1 · Reply
Timefortendies77
Timefortendies77 May. 12 at 2:02 PM
$BHVN the 27th-- day that will live in infamy-https://ventures.yale.edu/yale-innovation-summit-yale-ventures
0 · Reply
Latest News on BHVN
Biohaven price target lowered to $22 from $23 at RBC Capital

2026-05-05T12:31:27.000Z - 8 days ago

Biohaven price target lowered to $22 from $23 at RBC Capital

Biohaven price target lowered to $12 from $14 at BofA

2026-05-05T09:56:40.000Z - 8 days ago

Biohaven price target lowered to $12 from $14 at BofA

Biohaven files automatic mixed securities shelf

2026-05-04T20:38:11.000Z - 8 days ago

Biohaven files automatic mixed securities shelf

Biohaven reports Q1 adjusted EPS (69c), consensus (76c)

2026-05-04T20:15:04.000Z - 8 days ago

Biohaven reports Q1 adjusted EPS (69c), consensus (76c)

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

May 4, 2026, 4:02 PM EDT - 8 days ago

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

Biohaven initiated with a Buy at Canaccord

2026-04-13T11:06:28.000Z - 4 weeks ago

Biohaven initiated with a Buy at Canaccord

Biohaven price target raised to $17 from $14 at Citi

2026-04-02T10:30:20.000Z - 5 weeks ago

Biohaven price target raised to $17 from $14 at Citi

Biohaven completes enrollment in Phase 2 study on taldefgrobep alfa

2026-03-19T11:35:13.000Z - 7 weeks ago

Biohaven completes enrollment in Phase 2 study on taldefgrobep alfa

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Mar 19, 2026, 7:30 AM EDT - 7 weeks ago

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Biohaven price target raised to $30 from $15 at TD Cowen

2026-03-11T12:11:04.000Z - 2 months ago

Biohaven price target raised to $30 from $15 at TD Cowen

Biohaven price target raised to $27 from $24 at Goldman Sachs

2026-03-10T10:30:50.000Z - 2 months ago

Biohaven price target raised to $27 from $24 at Goldman Sachs

XENE

Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate

2026-03-09T17:50:26.000Z - 2 months ago

Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate

XENE

Biohaven fractionally lower after Xenon reports azetukalner Phase 3 hit target

2026-03-09T15:55:09.000Z - 2 months ago

Biohaven fractionally lower after Xenon reports azetukalner Phase 3 hit target

XENE

Biohaven price target lowered to $10 from $11 at H.C. Wainwright

2026-03-04T11:15:29.000Z - 2 months ago

Biohaven price target lowered to $10 from $11 at H.C. Wainwright

Biohaven price target lowered to $14 from $15 at BofA

2026-03-03T13:52:05.000Z - 2 months ago

Biohaven price target lowered to $14 from $15 at BofA

Biohaven reports Q4 adjusted EPS (90c), consensus (96c)

2026-03-02T21:15:50.000Z - 2 months ago

Biohaven reports Q4 adjusted EPS (90c), consensus (96c)

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Mar 2, 2026, 4:05 PM EST - 2 months ago

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Biohaven initiated with a Buy at Goldman Sachs

2026-02-05T21:23:15.000Z - 3 months ago

Biohaven initiated with a Buy at Goldman Sachs

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:15 AM EST - 4 months ago

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

Jan 7, 2026, 7:00 AM EST - 4 months ago

Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

Biohaven's depression drug fails mid-stage trial, shares fall

Dec 24, 2025, 3:24 PM EST - 4 months ago

Biohaven's depression drug fails mid-stage trial, shares fall

Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder

Dec 24, 2025, 1:00 PM EST - 4 months ago

Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder

Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

Dec 11, 2025, 7:00 AM EST - 5 months ago

Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M

Nov 13, 2025, 4:05 PM EST - 6 months ago

Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M

Biohaven Announces Pricing of $175 Million Public Offering of Common Shares

Nov 12, 2025, 7:15 AM EST - 6 months ago

Biohaven Announces Pricing of $175 Million Public Offering of Common Shares

Biohaven Announces Proposed Public Offering of Common Shares

Nov 11, 2025, 4:05 PM EST - 6 months ago

Biohaven Announces Proposed Public Offering of Common Shares

Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments

Nov 10, 2025, 6:58 AM EST - 6 months ago

Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments

Biohaven shares plunge after US FDA declines to approve brain disorder drug

Nov 5, 2025, 10:02 AM EST - 6 months ago

Biohaven shares plunge after US FDA declines to approve brain disorder drug

FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

Nov 4, 2025, 8:06 PM EST - 6 months ago

FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments

Aug 11, 2025, 7:00 AM EDT - 9 months ago

Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments

Law Offices of Frank R. Cruz Encourages Biohaven Ltd.

Jul 18, 2025, 12:06 PM EDT - 10 months ago

Law Offices of Frank R. Cruz Encourages Biohaven Ltd.

Law Offices of Howard G. Smith Encourages Biohaven Ltd.

Jul 18, 2025, 12:00 PM EDT - 10 months ago

Law Offices of Howard G. Smith Encourages Biohaven Ltd.

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biohaven Ltd. (BHVN)

Jul 15, 2025, 10:46 AM EDT - 10 months ago

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biohaven Ltd. (BHVN)

Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

Jun 10, 2025, 2:00 PM EDT - 1 year ago

Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

Ilygod
Ilygod May. 13 at 12:30 PM
$BHVN Institutions have been accumulating. You have to wonder if large Pharma is waiting for a change in FDA stance on SCA drug. If so, I bet it gets bought out for $25.
0 · Reply
Timefortendies77
Timefortendies77 May. 12 at 11:14 PM
$BHVN I didn't catch this before but after March 16 meeting with BHVN CEO and FDA CC, this meeting happened---Meeting Details from the FDA CalendarDate: April 30, 2026.Participants: Vlad Coric (CEO of Biohaven) and Several FDA staff members. Subject: Listed as "Issues of Mutual Interest"
0 · Reply
Timefortendies77
Timefortendies77 May. 12 at 11:08 PM
$BHVN Kyle D has the potential to be a "breath of fresh air" for industry relations compared to Marty, but whether he is "better" depends on your definition of success. M's tenure was defined by constant friction with pharmaceutical CEOs, mass staff departures, and erratic policy fights. [1, 2] Early market reactions to D’s appointment on May 12, 2026, suggest a cautiously optimistic view from the business community: [1] • Pragmatism Over Polemics: Unlike M, who frequently engaged in public spats, industry officials describe D as pragmatic, knowledgeable, and easier to work with. • A "Broad Positive" for Biopharma: Analysts from BioSpace noted that moving on from M could restore a level of predictability and trustworthiness to the regulator that was lost during the recent leadership churn.
0 · Reply
Timefortendies77
Timefortendies77 May. 12 at 10:55 PM
$RGNX Hi RGNX ---it's your pals over at $BHVN. What's the word on getting your drug reassessed given the change in FDA leadership?
2 · Reply
Timefortendies77
Timefortendies77 May. 12 at 10:53 PM
$BHVN Remember this tweet? @US_FDA exploring path forward for therapies that received CRLs $BHVN , $RGNX , Sydnexis held meetings w FDA’s chief counsel, Sean Keveney, following high-profile regulatory setbacks. Such meetings are highly unusual, writes BioCentury Washington Editor https://x.com/jeff_cranmer/status/2039127714599440671
0 · Reply
Timefortendies77
Timefortendies77 May. 12 at 10:51 PM
$BHVN BYE BYE MARTY! Time for our CRLed drug to get reassessed.
0 · Reply
jfoyle
jfoyle May. 12 at 5:26 PM
$BHVN He is officially gone! Huge re-rating coming for BHVN! https://www.nbcnews.com/health/health-news/dr-marty-makary-fda-commissioner-rcna344765
0 · Reply
Timefortendies77
Timefortendies77 May. 12 at 5:10 PM
$BHVN 8.85-9 is a gift with a significant update coming.
0 · Reply
jfoyle
jfoyle May. 12 at 3:11 PM
$BHVN Anything below $9 is a gift! May 27th on R&D day we will see a significant re-rating. Mark this post
1 · Reply
Timefortendies77
Timefortendies77 May. 12 at 2:02 PM
$BHVN the 27th-- day that will live in infamy-https://ventures.yale.edu/yale-innovation-summit-yale-ventures
0 · Reply
Timefortendies77
Timefortendies77 May. 12 at 2:00 PM
$BHVN We must hold 9!!!
0 · Reply
Timefortendies77
Timefortendies77 May. 12 at 12:47 PM
$BHVN Looks like BHVN had the 350M ATM traders start to sell yesterday while everyone's attention was elsewhere OR shorts just pushing it down while we wait for events. 9 always seems to be the FREEDOM level that it won't dip below even for a day. Good buying opp.
1 · Reply
HamBoneXoXo
HamBoneXoXo May. 11 at 9:03 PM
$BHVN So they burn over half a billion per year or nearly 1.5 million dollars per day. How would you burn $1.6 million in a day. My experience with such companies is there is frequent offering and nearly a constant ATM with an ever increasing outstanding. This just dilutes shareholder value. Too messy and they filed another shelf… Good luck as I don’t see a catalyst for the next few months
1 · Reply
sellthedip1
sellthedip1 May. 11 at 8:21 PM
$BHVN nice day for a buy 🙃
0 · Reply
pchr
pchr May. 11 at 2:23 PM
$BHVN long with commons and some calls from the 9.50s. such a shame there's not much volume in options
1 · Reply
Ccg_
Ccg_ May. 10 at 10:20 PM
$BHVN does Stocktwits know something we don’t? Lol
1 · Reply
Timefortendies77
Timefortendies77 May. 10 at 9:46 PM
$BHVN Catalysts COMING--1) Yale Biotech Innovation Conference the CEO mentions more people results on Degrader Platform Expanded Access Programs (may--whether CEO says anything specific TBD) 2) EPILEPSY (sept/oct) 3) Weight loss (dec). If you want to see what stocks do after successful Epilepsy--look at XENON---if you want to see what stocks do after successful Obesity (although not a dual action drug)--look at Scholar Rock. They aren't 10 a share.
0 · Reply
Timefortendies77
Timefortendies77 May. 10 at 9:34 PM
$BHVN Why is the weight loss drug SUCH a big deal? It is DUAL ACTION and right now no DUAL ACTION drugs are approved. This means it directly burns fat while building muscle - blocking both Myastin and Activin. Scholar Rock only works on muscles without the weight loss focus, so you have to take it with a GLP-1 drug. That is good, but most patients would prefer the one and done pill strategy. If Phase 2 trials succeed, this could easily be a drug bringing in Billions per year. And----this is only 1 of BHVN's programs. Raymond James put a target on it of 50 recently. Let's go!
0 · Reply
BioTechHealthX
BioTechHealthX May. 10 at 5:16 PM
$BHVN Biohaven Ltd. is not a safe, boring biotech stock. It is a clinical-stage company with pipeline catalysts in epilepsy, obesity, immunology, kidney disease, and Graves’ disease. With shares under pressure and several 2026 readouts ahead, BHVN could become a high-risk biotech comeback story. https://biotechhealthx.com/biotech-news/should-you-now-start-investing-in-biohaven-bhvn/
1 · Reply
BioTechHealthX
BioTechHealthX May. 10 at 4:21 AM
$ARQT $CDNA $NBIX $VCYT $BHVN These top 5 biotech stocks to buy for May 2026 are not just random healthcare names. With projected EPS growth reaching up to 215%, rising sales expectations, precision medicine exposure, and high-risk, high-reward biotech potential, this list could grab serious investor attention. https://biotechhealthx.com/biotech-news/top-5-biotech-stocks-to-buy-with-up-to-215-projected-eps-growth/
0 · Reply
Timefortendies77
Timefortendies77 May. 9 at 12:57 PM
$BHVN The absence of the March 16th (FDA CC and Biohaven CEO) meeting from the Biohaven earnings call does not necessarily mean the company has "moved on." Instead, it is likely due to the strict legal and regulatory boundaries that dictate what a company can publicly disclose regarding FDA interactions. Several strategic and legal reasons explain why such a meeting might be omitted from an earnings call: Materiality and SEC Rules: Under SEC regulations, companies are only required to disclose information that is "material"—meaning it would significantly influence an investor's decision. If the meeting was procedural or did not result in a definitive new regulatory outcome (like a formal trial protocol agreement), Biohaven may have determined it did not yet meet the threshold for a public update. Confidential Regulatory Dialogue: The FDA views meetings between a company's counsel and the agency's Chief Counsel as sensitive and non-public.
1 · Reply
Timefortendies77
Timefortendies77 May. 9 at 12:38 PM
$BHVN Reminder-'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process--Ron Johnson is pissed about the BHVN decision as is advocacy groups. With the FDA leader most likely on the way out, maybe we will get a relook at our CRLed Drug. This could change this stock quickly in the early term if a way forward is found. Note-BHVN met with FDA Chief Counsel March 16 and this was not discussed on earnings. Therefore, that means nothing is material enough to mention. Will that change? https://www.fiercebiotech.com/biotech/talking-brick-wall-senate-hearing-takes-aim-fdas-rare-disease-review-process
0 · Reply